1-3 of 3
Ellen van der Spek
Close
Sort by
Journal Articles

A significant proportion of classic Hodgkin lymphoma recurrences represents clonally unrelated second primary lymphoma

Diede A. G. van Bladel, Wendy B. C. Stevens, Leonie I. Kroeze, Ruben A. L. de Groen, Fleur A. de Groot, Jessica L. M. van der Last-Kempkes, Madeleine R. Berendsen, Jos Rijntjes, Jeroen A. C. W. Luijks, Irina Bonzheim, Ellen van der Spek, Wouter J. Plattel, Johannes F. M. Pruijt, Susan D. P. W. M. de Jonge-Peeters, Gerjo A. Velders, Chantal Lensen, Esther R. van Bladel, Birgit Federmann, Brigiet M. Hoevenaars, Agata Pastorczak, Jutte van der Werff ten Bosch, Joost S. P. Vermaat, Peet T. G. A. Nooijen, Konnie M. Hebeda, Falko Fend, Arjan Diepstra, J Han J. M. van Krieken, Patricia J. T. A. Groenen, Michiel van den Brand, Blanca Scheijen
Journal: Blood Advances
Blood Adv (2023) 7 (19): 5911–5924.
https://doi.org/10.1182/bloodadvances.2023010412
Published: 2023
Includes: Supplemental data
Journal Articles

IRF8 is a transcriptional activator of CD37 expression in diffuse large B-cell lymphoma

Clinical Trials & Observations
Suraya Elfrink, Martin ter Beest, Luuk Janssen, Marijke P. Baltissen, Pascal W. T. C. Jansen, Angelique N. Kenyon, Raymond M. Steen, Daynelys de Windt, Philipp M. Hagemann, Corine Hess, Dick-Johan van Spronsen, Brigiet Hoevenaars, Ellen van der Spek, Zijun Y. Xu-Monette, Ken H. Young, Charlotte Kaffa, Sander Bervoets, Jolien van Heek, Eva Hesius, Charlotte M. de Winde, Michiel Vermeulen, Michiel van den Brand, Blanca Scheijen, Annemiek B. van Spriel
Journal: Blood Advances
Blood Adv (2022) 6 (7): 2254–2266.
https://doi.org/10.1182/bloodadvances.2021004366
Published: 2022
Includes: Supplemental data
Journal Articles

Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL

Clinical Trials & Observations
Arnon P. Kater, Sabina Kersting, Yvette van Norden, Julie Dubois, Johan A. Dobber, Clemens H. Mellink, Ludo M. Evers, Fransien Croon-de Boer, John Schreurs, Ellen van der Spek, Hein Visser, Cecile Idink, Shulamiet Wittebol, Mels Hoogendoorn, Sanne H. Tonino, Mehrdad Mobasher, Mark-David Levin
Journal: Blood Advances
Blood Adv (2018) 2 (24): 3566–3571.
https://doi.org/10.1182/bloodadvances.2018019422
Published: 2018
Includes: Supplemental data